|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.97 USD | +0.51% |
|
+13.87% | -8.80% |
| 02/05 | Transcript : Cerus Corporation, Q1 2024 Earnings Call, May 02, 2024 | |
| 02/05 | Earnings Flash (CERS) CERUS CORPORATION Posts Q1 Revenue $43.4M, vs. Street Est of $38.4M | MT |
Cerus Corporation reiterated earnings guidance for the year ending December 31, 2024. The company is reiterating its full-year 2024 annual product revenue guidance range of $172 million to $175 million. Included in this range is full-year 2024 guidance for INTERCEPT Fibrinogen Complex, which is expected to be between $8 million to $10 million.
The company expects to report GAAP net loss attributable to the company for the full-year 2024.
| 1st Jan change | Capi. | |
|---|---|---|
| -8.80% | 362M | |
| +11.76% | 127B | |
| -5.10% | 11.32B | |
| +4.02% | 9.04B | |
| +38.12% | 5.56B | |
| -23.70% | 4.72B | |
| +8.55% | 3.45B | |
| -6.44% | 2.86B | |
| -5.85% | 2.07B | |
| -11.84% | 2.04B |
CERUS CORPORATION 
